Reply letter to 'safety of SARS-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance'
| Autor: | Rosaura Leis, Vanesa Crujeiras-Martinez, Nazareth Martinón-Torres, María L. Couce, Rebeca Saborido-Fiaño |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pharmacology
2019-20 coronavirus outbreak Pediatrics medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Adult patients business.industry Hereditary fructose intolerance Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology Fructose medicine.disease Clinical trial chemistry.chemical_compound chemistry medicine Immunology and Allergy Letters business |
| Zdroj: | Hum Vaccin Immunother |
| Popis: | In the letter, Urro et al. performed a search on the sucrose, fructose and sorbitol content in the approved Sars-Cov-2 vaccines and they concluded that these vaccines can be safely administered in adults affected by Hereditary fructose intolerance. The Pfizer-BioNTech COVID-19 Vaccine is currently approved for use in adolescents ≥ 12 years and the Moderna COVID-19 vaccine is close to approval for use in children over 12 years of age. Furthermore, both vaccines have initiated clinical trials that will include infant as young as 6 months. Therefore, we considerate important to analyze the safely administration of this two vaccines in children with Hereditary fructose intolerance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|